Regulatory approval

Published by the Health Service Executive. Approved

The Republic of Ireland's Health Service Executive (HSE) has approved vandetanib for reimbursement as a monotherapy treatment option for the treatment of patients with unresectable, locally advanced, or metastatic medullary thyroid cancer (MTC) that is Rearranged during Transfection (RET) mutation positive.

This is written in the approval document as:

Treatment of medullary thyroid cancer (MTC) in patients with Rearranged during Transfection (RET) mutation positive, unresectable locally advanced or metastatic disease.

Reimbursement

CDS

Citation

Vandetanib Therapy, 2026, version number 6, NCCP National SACT Regimen, NCCP, viewed 02/08/2026, https://healthservice.hse.ie/documents/6947/242_V5_Vandetanib_monotherapy.pdf

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies
HSE (1)	v::RET	Medullary Thyroid Cancer	Vandetanib

Contributions

Date	Contributor	Description
2024-01-16	Van Allen lab	Adding HSE approvals for reimbursement to database
2014-06-01	Health Service Executive	Indication approved for reimbursement.